These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16369892)

  • 21. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
    Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
    Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
    Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study.
    Komulainen M; Tuppurainen MT; Kröger H; Heikkinen AM; Puntila E; Alhava E; Honkanen R; Saarikoski S
    Osteoporos Int; 1997; 7(2):126-32. PubMed ID: 9166392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis.
    Ormarsdóttir S; Mallmin H; Naessén T; Petrén-Mallmin M; Broomé U; Hultcrantz R; Lööf L
    J Intern Med; 2004 Jul; 256(1):63-9. PubMed ID: 15189367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
    Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women.
    Armamento-Villareal RC; Napoli N; Klug T; Civitelli R
    Bone; 2004 Sep; 35(3):682-8. PubMed ID: 15336604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
    Orr-Walker BJ; Evans MC; Clearwater JM; Horne A; Grey AB; Reid IR
    Arch Intern Med; 2000 Jul; 160(14):2161-6. PubMed ID: 10904459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
    Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S
    Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum estradiol concentration as measured by HPLC-RIA and bone mineral density in postmenopausal women during hormone replacement therapy.
    Yasui T; Uemura H; Umino Y; Takikawa M; Kuwahara A; Saito S; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
    Horm Res; 2004; 61(3):117-25. PubMed ID: 14676459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
    Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y
    Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
    Ortiz Núñez DA; Mengchún López G; Hernández Marín I; Mendoza R; Ayala Ruíz AR
    Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
    Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
    Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
    Heikkinen J; Kyllönen E; Kurttila-Matero E; Wilén-Rosenqvist G; Lankinen KS; Rita H; Väänänen HK
    Maturitas; 1997 Mar; 26(2):139-49. PubMed ID: 9089564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy.
    Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR
    Maturitas; 2003 Jul; 45(3):175-83. PubMed ID: 12818462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
    Insua A; Negri A; Zanchetta JR
    Medicina (B Aires); 1995; 55(5 Pt 1):408-14. PubMed ID: 8728770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.